Besides the covid 19 vaccines that have been already deployed worldwide, experts everywhere are making great efforts to find a cure for covid as well.
There are multiple treatments that are being analyzed these days, and we’ll be addressing the one that Merck and AstraZeneca are working on.
It’s been just revealed by the online publication MarketWatch that the global number of confirmed cases of the coronavirus-borne illness covid 19 claimed above 238 million the other day.
Amidst the dramatic reports from all over the world triggered by the terrible disease, the US FDA saw an application coming from Merck submitted for emergency authorization – this could be the very first pill-based treatment for the deadly illness.
Quick update on state of the pandemic in the US in 4 graphs
First, nationally
We have clearly turned the corner on the delta surge
Now down 40% since peak a month ago
Still at high levels of infections and deaths
But good to be heading down as we head into fall and winter pic.twitter.com/uFKHcmz2Bg
— Ashish K. Jha, MD, MPH (@ashishkjha) October 10, 2021
Covid treatments in the works
It’s been just reported that Merck teamed up with partner Ridgeback Biotherapeutics, and had already said the following:
“data from a Phase 3 trial of the treatment, molnupiravir, an oral antiviral medicine, reduced the risk of hospitalization or death in adults at risk from severe covid 19 by 50%.”
As you definitely know by now, there are various effective vaccines that have been developed against the illness, but, on the other hand, far fewer treatments have emerged, and those that have “require infusions and must be administered in a clinical setting,” as the same online publication notes.
“Molnupiravir is a pill administered orally in capsule form every 12 hours for five days, according to clinicaltrials.gov.”
We addressed the fact that AstraZeneca, which is another essential player in the battle against Covid, said the following as reported by MarketWatch:
“high-level results from the AZD7442 long-acting antibody’s Phase 3 trial showed a statistically significant reduction in the risk of developing severe COVID-19 or death, as Dow Jones Newswires reported.”
Stay tuned for more news, and make sure that you and your loved ones remain safe.
